StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Let me help you out with that

<< Previous

Bullboard Posts

Next >>

Comment by Jonnyboy85on Apr 05, 2021 12:03am

79 Views

Post# 32935920

RE:RE:RE:RE:Let me help you out with that

Not sure why that link didn't work the first time but that seemed to do it.

Jonnyboy85 wrote:

Jonnyboy85 wrote: I understand that you're both missing the point intentionally, but just for fun I'll explain. See, Noel is our ONLY analyst, and that is our ONLY analyst rating despite your attempts to portray it otherwise. And you're right, when things change usually the analyst will update their rating.

Now that you have the CORRECT source, with the CORRECT rating of $4.00, by the person who has more information about our company than anyone, and more education when it comes to investing than anyone who has ever posted here, you can follow along when he makes his next update with the rest of us:)

and just in case you missed it the first time,

https://www.tipranks.com/analysts/noel-atkinson